ReviewJournal of fungi (Basel, Switzerland)2025
Development of Mycoinsecticides: Advances in Formulation, Regulatory Challenges and Market Trends for Entomopathogenic Fungi.
Review in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Delivery strategies for entomopathogenic fungi in crop pest management: a review.Pest management science · 2026Review
- Selecting effective nozzle-pressure combinations for successful foliar spray applications of Beauveria bassiana-based mycoinsecticide.Pest management science · 2026Article
- Endophytic Entomopathogenic Fungi Shape Herbivore Behavior and Plant-Insect Interactions: Implications for Biological Control.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Endophytic entomopathogenic fungi: The next frontier in mycological biocontrol.World journal of microbiology & biotechnology · 2026Review
- Screening of environmental fungi from Crete reveals candidates for biological control of mosquitoes.Journal of medical entomology · 2026Article
- Biopolymer-based seed biopriming with fungal endophytes suppresses Fusarium wilt and modulates growth in tomato.Frontiers in plant science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bioinsecticides offer eco-friendly alternatives to chemical insecticides and thereby meet the need for sustainable pest control. Entomopathogenic fungi (EPF) represent one of the core classes of microbial insecticides, distinguished by their advantageous contact-based mode of action. Several products have been successfully commercialized, and with continuing improvements to the technology, the market size for EPF continues to grow. The translation of EPF into reliable field performers relies upon formulation technologies that ensure product quality, stability, virulence, and cost-effectiveness. Current formulations comprise diverse solid and liquid states (e.g., wettable powders, oil dispersions) that deliver a range of propagules (conidia, blastospores, microsclerotia). While advanced approaches like nanoparticle encapsulation show promise, some limitations hinder their widespread use. Major constraints include maintaining fungal viability during storage/transport and protecting propagules from harsh environmental factors post-application. Regulatory requirements also present significant barriers to widespread uptake. Addressing these formulation challenges through continued research is essential for advancing mycoinsecticide technology and increasing their contribution to integrated pest management. This review aims to present the latest scientific advances in EPF formulation technologies and application strategies, alongside an overview of current regulatory frameworks and an up-to-date analysis of registered microbial biopesticide products in some of the world's largest markets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.